Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03622775 · ClinicalTrials.gov registry record · Phase 2
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03622775: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03622775 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03622775, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab and hyaluronidase-fihj with pomalidomide may help control the disease in patients with relapsed multiple myeloma.
Interventions
- BIOLOGICAL Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03622775
The ClinicalTrials.gov registry entry for NCT03622775 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daratumumab is the first listed.
NCT03622775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03622775 about?
NCT03622775 is a clinical study titled "Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant". This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer ...
What is the current status of trial NCT03622775?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-04-11. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT03622775?
The interventions under investigation include: Daratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03622775?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.